Degos Disease

Degos Disease is a rare condition that affects blood vessels. It causes small blood vessels to narrow and get blocked, which can lead to tissue damage. This can happen in different parts of the body, and it's not fully understood why it happens.

Condition

What people with Degos Disease report

Every report comes from a Lived member, sent anonymously.

Have you tried Aspirin for Degos Disease?

NameHow it went

About Degos Disease

What It Is

Degos disease, also called Köhlmeier-Degos disease or atrophic papulosis, is a very rare disorder of the small blood vessels. Affected vessels narrow and close off, so the tissue they supply loses its blood flow and small patches of it die. In the skin this produces a distinctive rash. In some people the same process damages internal organs, most often the bowel and the brain. The skin spots begin as small pink or red bumps, roughly half a centimeter to a centimeter across. Within days the center sinks and turns a porcelain white, surrounded by a red rim with tiny visible blood vessels. They usually appear on the trunk, arms and legs, and they often cause no itching or pain. Doctors separate two forms because their outlook is so different. In the benign form, the disease stays in the skin. In the malignant, or systemic, form, the skin spots are joined by damage to internal organs, which can be life-threatening. The name malignant atrophic papulosis refers to the systemic form, although it is sometimes used for the disease as a whole. Only a few hundred cases have been described in the medical literature.

Causes & Risk Factors

The cause of Degos disease is unknown. Researchers have proposed inflammation of the vessel walls, abnormal blood clotting and a primary problem in the cells lining the blood vessels, and these explanations may work together rather than compete. Recent studies have found signs of an overactive immune response involving interferons (signaling proteins of the immune system) and complement (blood proteins that drive inflammation). This research has guided some experimental treatments, but it has not settled the cause. The first skin spots most often appear in young and middle-aged adults, on average in the mid-30s, although cases in infants and children have been reported. Some families have more than one affected relative, which suggests an inherited contribution in some people, but most people with the disease have no affected relative. In a smaller group, similar-looking spots occur alongside an autoimmune connective tissue disease such as lupus or dermatomyositis. This secondary form appears less likely to involve internal organs. No lifestyle factor or exposure is known to trigger the disease.

How It's Diagnosed

Diagnosis rests mainly on the appearance of the skin spots, whose white centers and red rims are distinctive to a dermatologist who knows the condition. A skin biopsy, in which a small piece of an affected spot is removed and examined under a microscope, supports the diagnosis. The classic finding is a wedge-shaped area of damaged tissue beneath a blocked small artery, but it is not present in every sample, so a biopsy without it does not rule the disease out. Testing may also look for lupus and other autoimmune conditions, since they can produce similar spots. Once the diagnosis is made, the most important question is whether internal organs are involved, because that largely determines the outlook. Evaluation can include a brain MRI (magnetic resonance imaging) scan to look for brain involvement, camera examinations of the upper gut and colon (upper endoscopy and colonoscopy) to look for bowel lesions, and a chest X-ray and abdominal ultrasound to check the lungs and abdominal organs. Bowel damage in this disease tends to start on the outer surface of the intestine, where scans and endoscopy can miss it, so specialists sometimes use laparoscopy (a camera passed through a small cut in the abdomen) to look directly. Two common blood tests of inflammation, the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), were more often raised in people with systemic disease in one review of published cases. A raised result in someone with Degos disease can point toward internal involvement, but many people with systemic disease have normal results, so normal values are not reassurance on their own.

Treatment Options

No treatment has been proven to work for Degos disease, and none reliably prevents or stops the systemic form. Because the disease is so rare, almost all treatment experience comes from individual case reports and small case series rather than controlled trials. Published results are hard to compare and may overstate success, since unusual responses are more likely to be reported. For disease limited to the skin, some people are simply monitored, and others take medicines that make blood less likely to clot in small vessels. Aspirin and dipyridamole make platelets (the blood cells that start clots) less sticky, and pentoxifylline helps blood flow through small vessels. These have led to partial fading of skin spots in some reports and are a common first approach. In a 2021 review of published cases, a single antiplatelet medicine was followed by complete clearing in about 4 of 10 reported skin-only cases and 2 of 10 systemic cases, figures based on a few dozen patients. For systemic disease, specialists have used eculizumab (Soliris) and treprostinil (Remodulin), neither of which is approved for Degos disease. Eculizumab is an infused antibody that blocks part of the complement system. It improved skin and bowel lesions in some reported patients but did not always prevent the disease from progressing, and because it raises the risk of serious meningococcal infection (a dangerous bacterial infection of the blood or brain lining), meningococcal vaccination is required before starting it. Treprostinil, approved for high blood pressure in the arteries of the lungs, widens blood vessels and reduces platelet clumping. Given by injection under the skin, it was followed by marked improvement in a report of two patients, including one whose disease had progressed on eculizumab. Immune-suppressing treatments such as corticosteroids, cyclosporine and azathioprine have mostly been unsuccessful, and some patients have worsened while taking them. Research into interferons has led to early testing of ruxolitinib, a JAK (Janus kinase) inhibitor that dampens interferon signaling, which in one patient was associated with calmer skin inflammation and stable neurological disease. Complications in internal organs are treated directly, for example with surgery for a hole in the bowel. Care is usually led by a dermatologist working with gastroenterology, neurology and other specialists, ideally with input from a center that has treated the disease before.

What to Expect

The outlook depends mostly on whether internal organs become involved. People whose disease stays in the skin generally do well. In the largest long-term studies from a specialist center, no one with skin-only disease died of it, and the spots can persist for years or for life, often without symptoms. Systemic disease is serious. It most often affects the bowel and the brain, and less often the eyes, the linings of the lungs and heart, or the kidneys. Blocked vessels can lead to holes in the bowel, strokes or bleeding in the brain. When it happens, internal involvement usually appears within a year or two of the first skin spots, but it has been reported many years later. In one prospective study, about 3 in 10 people developed systemic disease. The chance of staying skin-only was about 70% at the start and rose to about 97% for people whose disease had remained in the skin for 7 years. Reported death rates for the systemic form vary widely: about a quarter of patients in the larger study from one specialist center, nearly three quarters in its earlier, smaller prospective study, and more than half in collections of published case reports. Because internal involvement can develop without warning, regular follow-up matters even when the skin is the only area affected. Experts recommend at least a yearly review that includes a skin check and tests for internal organ involvement. With a disease this rare, it is worth seeking a clinician who has managed it before, and it can help to keep a written summary of your diagnosis and tests to share with other doctors.

When to Seek Help

See a dermatologist if you notice small spots with sunken white centers and a red rim that do not go away. If you have Degos disease, contact your care team right away about new or ongoing abdominal pain, blood in your stool, double vision or other vision changes, new numbness or headaches that persist, or chest pain when you breathe. Abdominal pain often comes before a hole in the bowel develops, and treatment is simpler and safer before that happens. Sudden severe abdominal pain, especially with fever, chills, vomiting or feeling faint, can mean a perforated bowel and needs emergency care right away. Call 911 for signs of a stroke, such as sudden face drooping, weakness of an arm or one side of the body, slurred or strange speech, or a sudden severe headache.

Questions to Ask Your Doctor

  1. 1.Do my tests show any sign that internal organs are involved, and how will we keep checking for it?
  2. 2.Which follow-up tests do you recommend each year, and who coordinates them?
  3. 3.What are the realistic benefits and risks of antiplatelet treatment for my skin lesions?
  4. 4.If systemic disease develops, which treatments or clinical studies would be options, and which centers have experience with Degos disease?

Last reviewed • Oct 2026

Educational content, not medical advice.